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ABSTRACT Acute lung injury (ALI) in mouse lung
occurs after distal airway deposition of IgG immune
complexes (IgGICs), resulting in a breakdown of the
vascular-airway barrier, causing intrapulmonary edema,
hemorrhage, and accumulation of neutrophils [poly-
morphonuclear leukocytes (PMNs)] in the alveolar
compartment, these changes being complement (C5a)
and C5a receptor (C5aR) dependent. In this ALI
model, C5aR expression (protein) was found to occur
on upper (bronchial) and lower (alveolar) airway epi-
thelial cells. An adenovirus construct (siRNA) was used
to silence mRNA for C5aR in the lung. Under such
conditions, C5aR protein was markedly reduced on
lung epithelial cells, resulting in much reduced leakage
of albumin into the lung, diminished buildup of PMNs,
and lower levels of proinflammatory mediators in bron-
choalveolar lavage fluids. These studies indicate that
bronchial and alveolar epithelial cell C5aR is up-regu-
lated and greatly contributes to inflammation and injury
in the lung. The use of siRNA administered into the
airways avoids systemic suppression of C5aR, which
might compromise innate immunity. It is possible that
such an intervention might be employed in humans with
ALI or acute respiratory distress syndrome as well as in
upper-airway inflammatory diseases, such as chronic
obstructive pulmonary disease and asthma, where there
is evidence for complement activation and buildup of
PMNs.—Sun, L., Guo, R.-F., Gao, H., Sarma, J. V.,
Zetoune, F. S., Ward, P. A. Attenuation of IgG immune
complex-induced acute lung injury by silencing C5aR in
lung epithelial cells. FASEB J. 23, 3808–3818 (2009).
www.fasebj.org
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The rodent lung injury model triggered by the
intrapulmonary deposition of IgG immune complexes
(IgGICs) is used to study the roles of cytokines, chemo-
kines, and complement in the induction of acute
inflammation (1). In this model, IgGIC deposition
triggers complement activation and activation of resi-
dential lung macrophages via engagement of FcRs.
One of the complement activation products, C5a, has
been demonstrated to be required for the full develop-
ment of injury and neutrophil accumulation in an
IgGIC model of lung injury (2). Together with other
cytokines/chemokines and vascular adhesion mole-
cules, C5a is required for recruiting leukocytes from the
vascular space into the interstitial and distal airway
compartments (3–6). C5a also directly activates neutro-
phils and macrophages for chemokine production.
Both in vitro and in vivo studies have shown that, in the
presence of IgGIC, C5a and MAC (C5b-9, membrane
attack complex) cause synergistic intrapulmonary gen-
eration of rat CXC (MIP-2 and CINC) and CC (MIP-1,
MIP-1, and MCP-1) chemokines, resulting in in-
creased neutrophil accumulation as well as intensified
lung injury (7, 8). C5a can also activate endothelial and
alveolar epithelial cells, resulting in the release of
proinflammatory mediators, thereby setting the stage
for neutrophil migration. C5a increases CD11b/CD18
(CR3) expression in neutrophils and enhances adhe-
sive interactions of both neutrophils and eosinophils to
unstimulated human umbilical vein entotheilial cells
(HUVECs) and to human bronchial epithelial cells (9,
10). C5a is also involved in the up-regulation of vascular
adhesion molecules such as P- and E-selectin and
ICAM-1 in the lung (11, 12).
C5a induces its inflammatory functions by interact-
ing with the C5a receptor (C5aR) that belongs to the
rhodopsin family of 7-transmembrane G-protein-cou-
pled receptors (13–15). Originally thought to be exclu-
sively expressed in myeloid bone marrow cells (16),
neutrophils (17), monocytes (18), basophils (19), and
eosinophils (20), recent studies have demonstrated the
presence of C5aR in other cell types, such as bronchial
and alveolar epithelial cells (21–23), kidney tubular
epithelial cells (24), astrocytes (25), hepatocyte-derived
cell lines (26), and endothelial, smooth muscle, and
other parenchymal cells of solid organs, including the
liver, kidney, and lung (27–31). Up-regulation of C5aR
has been seen under pathological conditions (32, 33).
In septic animals, increased expression of C5aR was
detected in organs including the heart, liver, lungs, and
kidneys (34). Studies from our group have shown that
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blockade of either C5a or C5aR (using IgG antibodies
or a C5aR antagonist) results in a significant improve-
ment in survival rates in a rodent model of sepsis after
cecal ligation and puncture (CLP) (35–37). The pro-
tective effects of C5a blockade appeared to derive from
the interception of C5a/C5aR signaling, because block-
ade of C5aR achieved a similar level of improvement in
survival of CLP animals (34). In IgGIC-induced lung
injury model, C5aR antagonist treatment markedly
reduced the lung permeability index (extravascular
leakage of albumin) in mice (37). Consistently, mice
deficient in C5aR were protected from IC-induced
alveolitis (38, 39).
Due to the detrimental effects of complement activa-
tion under pathological conditions, interventions aimed
at blocking C5a or C5aR signaling may represent a
promising target for therapeutic treatment in inflam-
matory disorders. In the progression of acute lung
injury, it is unclear to what extent C5aR in epithelial
cells contributes to the detrimental outcome. Previ-
ously, we reported the in vivo knockdown of C5aR gene
expression with intrapulmonary infection of siRNA-
expressing adenovirus, but where knockdown occurred
in the lung was not determined, nor was any functional
significance of this knockdown assessed (40). In the
current study, we took advantage of adenovirus-target-
ing infection of epithelial cells in the lung to address
the role of C5aR expression in epithelial cells in the
lung injury induced by IgGIC deposition.
MATERIALS AND METHODS
All experiments were done with the approval of the University
of Michigan University Committee on Use and Care of
Animals (UCUCA).
Reagents
Rabbit anti-BSA IgG was purchased from ICN Biomedicals
(Irvine, CA, USA). ELISA kits for mouse IL-6, keratinocyte-
derived chemokine (KC), and TNF- were purchased from
Biosource International (Camarillo, CA, USA). The ELISA
kit for the detection of mouse albumin levels in bronchial
alveolar lavage (BAL) fluids was purchased from Bethyl Labs
(Montgomery, TX, USA). The detection limit for this ELISA
was 7 ng/ml.
A 37-aa peptide spanning the N terminus of the mouse C5aR
(MDPIDNSSFEINYDHYGTMDPNIPADGIHLPKRQPGDC) was
synthesized using an Applied Biosystems 430A peptide syn-
thesizer (Applied Biosystems, Foster City, CA, USA). The
peptide was then coupled to keyhole limpet hemocyanin by
the glutaraldehyde method and used for the immunization of
rabbits and the production of immunoreactive antisera. The
anti-peptide-specific Ab was purified by affinity chromatogra-
phy using the synthetic peptide coupled to cyanogen bro-
mide-activated Sepharose 4B (Amersham Pharmacia Biotech,
Piscataway, NJ, USA).
Adenovirus
An adenovirus that expresses the short hairpin RNA of C5aR
(adeno-C5aR-shRNA) or luciferase (adeno-luc-shRNA; con-
trol virus) was described previously (40). The virus-expressing
vector contains a dsRed fluorescent protein cDNA. Viruses
were produced by infecting HEK293 cells. Briefly, cells were
infected with 5–10 MOI of stock virus and incubated at 37°C
for 2–3 d until 80–90% of the cells rounded up and started to
float. Cells were spun down and lysed in PBS with 3 consec-
utive freeze-thaw cycles. Supernatants containing infectious
adenoviruses were purified by column (Puresyn, Inc.,
Malvern, PA, USA) and concentrated by YM-50 centricon
(Millipore, Billerica, MA, USA). Titers of the viruses were
determined by Adeno-X rapid titer kit (BD Clontech, Moun-
tain View, CA, USA).
Intratracheal administration of adenovirus
Adenoviral suspensions (50 l) with a dosage of 5  108
plaque-forming units was injected intratracheally into mouse
lungs, using a Hamilton syringe with a sterile 30-gauge
needle. Four days later, mice were used for IgGIC-induced
lung injury.
IgGIC-induced lung injury
Eight- to 10-wk-old specific-pathogen-free male C57BL/6
mice were anesthetized with ketamine-HCl (150 mg/kg, i.p.).
The trachea was surgically exposed by a midline incision, and
100 g of rabbit anti-BSA IgG in 40 l of PBS was adminis-
tered intratracheally with a 30-gauge needle. The incision was
closed by two surgical clips, and 1 mg of BSA in 200 l of PBS
was injected intravenously immediately thereafter. Control
mice received anti-BSA intratracheally in the absence of an
intravenous infusion of BSA.
Animals were sacrificed 4 h after IgG-IC-induced alveolitis.
This interval selected for sacrifice represents the time for
peak lung injury as determined in previous experiments (1).
Four hours after initiation of the acute lung injury, the thorax
was opened and 0.8 ml of ice-cold, sterile PBS was instilled
into the lung via a tracheal incision. The recovered BAL fluid
was centrifuged at 450 g for 6 min, and the cell-free superna-
tants were stored at 20°C. Lung tissues were harvested,
snap-frozen in liquid nitrogen, and stored at 80°C.
Lung pathology
Four days after virus injection, the lungs were inflated with 0.8
ml of tissue-embedding solution (Tissue-Tek OCT com-
pound; Fisher Scientific, Pittsburgh, PA, USA) before being
frozen to prevent alveolar collapse. Glass slides with tissue
sections of 4–5 m thickness were examined under fluores-
cence microscope (lissamine-rhodamine channel) for virus
distribution in the lung.
Quantification of C5aR mRNA by Sybr green real-time PCR
analysis
Lung total RNA was isolated with the Trizol method. Reverse
transcription was performed with 1 g RNA using the high-
capacity cDNA reverse-transcription kit (Applied Biosystems).
Sybr green real-time PCR was then performed with primers for
C5aR: forward primer, 5-GAAGCGGCAACCTGGGGATGT-3
and reverse primer, 5-CGTCTGGCTCGAAGGCTGTCAC-3.
The Taqman assay was used for the quantification of endoge-
nous control (GAPDH; Applied Biosystems). Results were nor-
malized to GAPDH expression and presented as fold increase in
mRNA expression compared with the level detected in control
mice. Real-time PCR assay was performed on an Eppendorf
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Realplex cycler (Eppendorf North America, Westbury, NY,
USA).
Permeability index
For permeability index measurements, BSA was labeled with
125I by the chloramine T method. A trace amount of 125I-BSA
(specific activity 5 Ci/g) was added to unlabeled BSA (5
mg/ml in PBS), and 200 l of this solution was injected
intravenously to induce the IgGIC lung injury, as described
above. Four hours later, mice were euthanized, and blood was
collected from the inferior vena cava. The thorax was opened,
the left atrium was incised, and the lung was perfused in situ
with 3 ml PBS via the pulmonary artery. The flushed lungs
were removed, and the permeability index (indicating the
extent of pulmonary leakage) was determined by using a 
counter and expressed as a ratio of counts per minute in the
whole lung vs. radioactivity in 100 l of blood.
Myeloperoxidase (MPO) activity
Animals were sacrificed, and lungs were perfused via the right
ventricle using PBS until pulmonary vessels were grossly clear.
Tissues were weighed and homogenized in a homogenate
buffer: 0.5% hexadecyltrimethylammonium bromide and 5
mM EDTA in 50 mM potassium phosphate buffer, pH 6.0.
The samples were sonicated for 1 min and then centrifuged at
20,000 g for 15 min. Ten microliters of each sample was
added to a 96-well plate, followed by addition of 250 l assay
buffer: 0.005% H2O2 and 0.5 mM o-dianisidine dihydrochlo-
ride in 100 mM potassium phosphate, pH 6.0. The change in
optical density (OD) at 460 nm was measured over a period of
6 min at 15-s intervals, using the kinetics mode in a spectro-
photometer (Molecular Devices). The slope of the change in
OD was calculated to reflect the rate of change in units per
gram of lung per minute. All samples were diluted 1:5 to
guarantee a linear response.
BAL and in vitro IgGIC treatment
Four days after virus injection, BAL fluids were collected
using repetitive (3 times) instillation and withdrawal of 1 ml
saline via an intratracheal cannula. BAL samples were centri-
fuged at 1500 rpm for 10 min, and cell pellets were resus-
pended in RPMI  10% fetal calf serum and plated in 96-well
plates. Alveolar macrophages were allowed to adhere at 37°C
for 1 h, and nonadhering cells were removed. To induce IC
formation in vitro, 100 g of BSA in 100 l of PBS buffer was
incubated with a 5-fold excess of anti-BSA IgG at room
temperature for 30 min and then was added to cells. At the 2
and 18 h time points, the supernatants were removed from
culture and measured for TNF- production.
Immunohistochemical staining for C5aR
Mice were injected with adenoviruses as described above.
Four days later, mice were used for IgGIC-induced lung
injury. Four hours after initiation of injury, the lungs were
inflated with OCT, and glass slides with tissue sections of 4–5
m thickness were processed for immunohistochemical stain-
ing. The slides were first washed with PBS for 10 s and then
fixed in methanol for 6 min. Next, the tissue sections were
washed for 2 min with PBS before incubation with anti-C5aR
serum at a dilution of 1:100 for 2 h. Thereafter, the tissue
sections were washed for 2 min with PBS before incubation
with a 1:500 diluted peroxidase-conjugated goat anti-rabbit
IgG for 30 min (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA). After being washed with PBS for 2 min, the
sections were stained using the AEC vector staining kit
(Vector Laboratories, Burlingame, CA, USA). Counterstain-
ing was achieved with hematoxylin for 30 s. Tissue sections
were fixed, and the coverslides were mounted with Permount
medium (Fisher Scientific). Staining was documented using
light microscopy and digital imaging.
Figure 1. Sections of mouse lung after intratracheal administration of
adenovirus and induction of IgGIC-induced injury. A, B) Assessment of
adenovirus distribution in lung after intratracheal administration
of dsRed fluorescence protein-expressing adenovirus. Four days after
virus injection, lung sections were examined, and dsRed protein was
visualized in the lissamine-rhodamine channel under fluorescence
microscopy. A) Bright-field image of infected lung (20). B) Abundant
red fluorescence of lung receiving dsRed virus in bronchiolar (left)
and alveolar (center) walls (20). C) Four days after intratracheal
injection of either buffer control (PBS), C5aR-siRNA silencing virus
(C5aR-siRNA), luciferase control virus (Luc siRNA control virus), or scrambled siRNA control virus (Sc siRNA control
virus), mice were subjected to IgGIC-induced lung injury. Lung total RNA was isolated 4 h after injection of IgGIC injury
and analyzed for mRNA for C5aR by real-time PCR analysis. Data are expressed as relative fold changes over nonvirus
infected, control lungs (buffer control group). Results are means 	 se; 5 mice/group.
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Pulmonary leukocyte isolation
Animals were euthanized by approved protocols, and individ-
ual mice were used to collect cells for flow cytometry. First,
BAL was performed as described above, and then lungs were
perfused with PBS via the right heart until pulmonary vessels
were grossly clear. The lungs were bluntly dissected free from
the chest cavity and minced in complete medium (RPMI10%
fetal calf serum) containing collagenase (15 mg) and DNase I
(250 Kunitz units). The suspension was incubated on a rocker
for 30 min at 37°C. The cells were dispersed by repetitive suction
through a 10-ml syringe and then spun down at 1100 rpm for 10
min. After the supernatant was decanted, each pellet was briefly
resuspended with 1 ml sterile ddH2O to lyse red blood cells and
then recentrifuged. Cell pellets were resuspended in 5 ml of
complete medium and passed through a 70-m cell strainer.
Flow cytometric analysis for C5aR
Both BAL cells and lung leukocytes were assessed for flow
cytometric analysis. BAL cells (50,000 cells) in 100 l flow
assay buffer were first incubated with 0.2 g of mouse Fc
blocker (BD Pharmingen, San Jose, CA, USA) for 15 min and
then stained with 10 l of anti-C5aR IgG for 30 min at room
temperature. After being washed, the cells were labeled with
FITC-conjugated goat anti-rabbit IgG (1:50; Biosource, Carls-
bad, CA, USA) and simultaneously stained with APC-conju-
gated anti-F4/80 IgG (Biolegend, San Diego, CA, USA). Cells
were washed again, resuspended in a fixation buffer (1%
paraformaldehyde in PBS with 0.1% sodium azide), and
analyzed on a flow cytometer (Accuri C6; Accuri Cytometers
Inc., Ann Arbor, MI, USA). To assess both cell surface and
intracellular C5aR expression, cells were first stained with
APC-conjugated anti-F4/80 IgG and then fixed and perme-
abilized with 4% paraformaldehyde and 0.1% saponin. The
permeabilized cells were reacted with anti-C5aR IgG, followed
by staining with FITC-conjugated goat anti-rabbit IgG, and
then washed and subjected to flow cytometry analysis. Whole-
lung leukocytes were stained using the same procedure as
BAL cells, except that 400,000 leukocytes were used in each
experimental group. Both nonpermeabilized and permeabil-
ized lung leukocytes were assayed for C5aR expression.
Statistical analysis
All values were expressed as means 	 se. Significance was
assigned where P 
 0.05. Datasets were analyzed using
Student’s t test or 1-way ANOVA, with individual group means
being compared with the Student-Newman-Keuls multiple
comparison test.
RESULTS
Adenovirus-mediated C5aR-siRNA silencing attenuates
the up-regulation of C5aR mRNA induced by IgG-IC
deposition
Recently, we demonstrated that in vivo use of the
C5aR-siRNA adenovirus construct attenuated C5aR ex-
pression in lungs from normal mice and after cecal
ligation and puncture-induced sepsis in mice (40).
However, the details of what happened in the lung and
the functional significance were not evaluated. We have
now investigated the effects of in vivo C5aR silencing in
acute lung injury induced by distal airway deposition of
IgGICs. First, we examined whole-lung C5aR mRNA
expression 4 h after the initiation of injury. In all the
experiments, we used a dose of 5.0  108 plaque-
forming units for intratracheal virus injection 4 d
before acute lung injury induction. The protocol used
Figure 2. Effects of C5aR-siRNA silencing on intensity of IgGIC-
induced lung injury. A) Four hours after the onset of IgGIC-
induced injury, BAL fluids were harvested, and mouse albumin
levels in the BAL fluids were measured by ELISA as an index of
vascular leakage; n  5 mice/group. B) Trace amounts of
125I-labeled BSA were added to the unlabeled BSA and injected
intravenously to induce the IgGIC-induced lung injury. Albumin
leakage into the lung (permeability index) was determined 4 h
after the injury and expressed as the ratio of 125I-BSA in perfused
lung to that in 100 l serum obtained at the time of sacrifice;
n  5 mice/group.
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in our experiments achieves maximum silencing with-
out triggering an intrapulmonary inflammatory re-
sponse (40). As shown in Fig. 1A, B, adenoviral infec-
tion was displayed as red-colored fluorescence that
became prominent 4 d after infection. The viral infec-
tion was widely distributed in lung tissue especially in
bronchial epithelial cells and lung alveolar epithelial
cells (Fig. 1B).
Next, mRNA for C5aR was evaluated by real-time
PCR. Mice that received intratracheal injection of PBS
buffer served as a negative control (Fig. 1C, 1st vertical
bar). Mice receiving luciferase siRNA (Fig. 1C, 2nd
vertical bar; Luc siRNA control virus) and scrambled
siRNA control virus (Fig. 1C, 3rd vertical bar; Sc siRNA
control virus) intratracheally but no IC injury served as
controls. C5aR mRNA was up-regulated 4 h after IC
deposition (Fig. 1C, 4th and 5th vertical bars). How-
ever, in the presence of C5aR-siRNA adenovirus, the
injury-induced up-regulation of C5aR in the lung was
reduced by 62% when compared with mice that re-
ceived control viruses. Not surprisingly, control virus
infection in the lung (Fig. 1C, 2nd and 3rd vertical
bars) caused a modest increase in C5aR mRNA levels.
As will be shown, this did not result in a lung inflam-
matory response. These data indicate that the adenovi-
rus-expressed C5aR siRNA effectively suppresses C5aR
expression in vivo in the lung after IgGIC-deposition.
As we did not find any difference between luciferase
siRNA virus and scrambled siRNA virus in lung C5aR
expression in either control mice or IC-challenged
mice, luciferase siRNA virus was used as control in the
subsequent experiments.
Lung vascular permeability is reduced by in vivo
silencing of C5aR-siRNA
To examine whether siRNA-induced suppression of
C5aR affects lung injury after IgGIC deposition, we
measured leakage of mouse albumin into the lung.
Endogenous mouse albumin levels in BAL fluids were
measured by ELISA. In mice that received PBS intra-
tracheally, albumin remained at background levels
(Fig. 2A, 1st and 2nd vertical bars). In mice that
received intratracheal administration of control virus
together with IgGIC deposition, high levels of albumin
were detected in the BAL fluids (Fig. 2A, 3rd vertical
bar). In contrast, when IC lung injury developed in
mice receiving intratracheal injection of C5aR-siRNA
virus, the albumin level in the BAL fluid was reduced
almost to background levels (Fig. 2A, 4th vertical bar).
A similar result was obtained when I125-labeled BSA was
employed to measure the leakage of intravenously
infused BSA into lung tissue (Fig. 2B). The levels of
Figure 3. Effects of C5aR-siRNA
silencing on lung MPO content
and BAL levels of TNF-, IL-6,
and KC. Mice received adenovi-
rus 4 d before induction of
acute lung injury. Whole-lung
homogenates were analyzed for
MPO activity 4 h after the onset
of injury. A–D) BAL fluids ob-
tained 4 h after the onset of
injury were analyzed for expres-
sion levels of MPO (A), TNF-
(B), IL-6 (C), and KC (D) by
ELISA. E) Alveolar macro-
phages were isolated from both
control mice and C5aR siRNA
virus-challenged mice, and
their ability to produce TNF- when treated with immune complexes in vitro was assessed; n  6 – 8 mice/group.
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125I-BSA fluids of mice receiving PBS or control virus
intratracheally were similar (Fig. 2B, 1st and 2nd verti-
cal bars). A significant decrease in the permeability
index was found in IC-injured mice that received
intratracheal administration of the C5aR-siRNA virus
compared with IC-injured mice that received the con-
trol virus (Fig. 2B, 3rd and 4th vertical bars).
Effects of C5aR-siRNA silencing on MPO content
and cytokine/chemokine levels in IgGIC-injured lung
Having found that the degree of lung injury (repre-
sented by albumin leakage into the lung) was reduced
by in vivo expression of C5aR-siRNA (Fig. 2), we exam-
ined MPO content in the lung, which is an indicator of
neutrophils present in the lung. Virus administration
alone did not cause an increase in MPO activity in the
lung (Fig. 3A, 1st and 2nd vertical bars). Four hours
after the onset of IC injury, dramatically increased
MPO activity was detected (Fig. 3A, 3rd vertical bar) in
mice infected with the control virus. In mice infected
with C5aR-siRNA virus, there was a significant reduc-
tion (Fig. 3A, 4th vertical bar; P
0.01 vs. 3rd bar). The
reduced MPO content in the lung correlated with the
reduced vascular permeability (Fig. 2). We also evalu-
ated the effects of C5aR-siRNA silencing on levels of
proinflammatory cytokines/chemokines in BAL fluids
4 h after IgGIC deposition. Virus infection alone, in the
absence of IC injury, did not increase the levels of these
proinflammatory mediators (Fig. 3B–D, 1st and 2nd
vertical bars). In IgGIC-injured lungs, C5aR-siRNA virus
administration led to significantly decreased levels of
Figure 4. In vivo C5aR-siRNA silencing attenuated C5aR expression in lung epithelial cells. Mice were infected with control virus
(A–C) as well as C5aR-siRNA virus (D) 4 d before IgGIC-induced lung injury for 4 h (C, D). Immunohistochemical analysis was
performed on mouse lungs stained with control serum (A) or anti-mouse C5aR serum (B–D; 20). Arrows indicate alveolar
epithelial cells; open arrowheads indicate alveolar macrophages; solid arrowheads indicate bronchiolar epithelial cells. Results
are means 	 se; 5 mice/group.
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TNF-, IL-6, and KC (by 80, 57, and 62% respectively),
when compared with mice that were administrated
control virus (Fig. 3B–D, 3rd and 4th vertical bars).
These data suggest that C5aR silencing can strongly
inhibit lung inflammatory responses and neutrophil
accumulation after IgGIC-deposition.
To assess whether in vivo silencing of C5aR affects the
functionality of lung alveolar macrophages, we con-
ducted an in vitro IgGIC stimulation experiment. Alve-
olar macrophages from either control mice or C5aR
siRNA virus-challenged mice were isolated and incu-
bated with IgGIC in vitro. In both groups, TNF-
production was strongly induced with the addition of
IgGICs. However, no difference was found between
control and C5aR siRNA virus groups at both the 2 and
18 h time points examined (Fig. 3E). These data
suggest that the capability of alveolar macrophage
to release inflammatory mediators was not altered by
in vivo delivery of C5aR siRNA virus.
Adenovirus-mediated in vivo silencing of C5aR in lung
epithelial cells
In Fig. 1, we found that C5aR mRNA in whole lung was
reduced by in vivo silencing with C5aR-siRNA. To
further investigate the specific cell types in the lung
that were affected by the intratracheal administration
of adenovirus C5aR-siRNA, we examined the expres-
sion of C5aR in frozen sections of the lung by immu-
nohistochemistry for C5aR protein. To localize the cells
in the lung that were targeted by C5aR-siRNA silencing,
we performed immunohistochemical staining in lung
frozen sections after 4 d of virus administration (Fig. 4).
Lung sections from mice that received control virus but
did not undergo IgGIC-induced lung injury served as
controls (Fig. 4A, B). With anti-mouse-C5aR staining,
low levels of C5aR protein expression were detected in
lungs treated with control virus (Fig. 4B). The patterns
of staining were mainly in bronchiolar (Fig. 4B; solid
arrowheads) and alveolar epithelial cells (Fig. 4B; open
arrowheads). With induction of IC-induced injury, the
C5aR signal was greatly intensified in mice that received
control adenovirus (Fig. 4C). There was intensified
staining in bronchial epithelial cells (Fig. 4C; solid
arrowheads) and in the alveolar compartment where
staining involved both alveolar epithelial cells (Fig. 4C,
arrows) and alveolar macrophages (Fig. 4C, open
arrowheads). However, in injured mice that received
C5aR-siRNA virus, the C5aR signal was attenuated,
especially in bronchial and alveolar epithelial cells
(Fig. 4D).
Adenovirus-mediated in vivo delivery of C5aR siRNA
did not silence C5aR expression in BAL and
interstitial macrophages
To further quantify C5aR expression in alveolar mac-
rophages (in BAL fluid), we did flow cytometric analysis
on BAL cells obtained in BAL fluids under noninjury
conditions (Fig. 5A). Initial gates were set based on
Figure 5. Flow cytometric analysis of in vivo C5aR-siRNA silencing on C5aR expression in alveolar macrophages. BAL fluids from
mice infected with control virus or C5aR-siRNA virus were isolated as described in Materials and Methods. Alveolar
macrophages, which represent 80–90% of cell population in BAL fluids, were identified by positive staining for F4/80.
Expression of C5aR on alveolar macrophages was examined under both nonpermeabilized (A) and permeabilized conditions
(B). Overlay analysis showed that expression of C5aR on alveolar macrophages was not changed by in vivo C5aR-siRNA silencing.
Experimental data represent measurements from 4 mice/group.
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light-scattering characteristics to eliminate debris, red
cells, and cell clusters. Alveolar macrophages were
identified with a macrophage marker (F4/80). In BAL
fluids, 80% of the cells were macrophages (Fig. 5;
F4/80-positive gating). C5aR expression was compared
in the gated macrophages. Intratracheal administration
of control adenovirus or C5aR-siRNA adenovirus 4 d
prior did not change the levels of C5aR expression in
macrophages retrieved from otherwise normal lungs
(no virus or control virus-challenged mice). As receptor
internalization was reported for C5aR (41–43), we also
examined C5aR expression in permeabilized alveolar
macrophages (Fig. 5B). BAL cells were permeabilized
by saponin and then stained with anti-C5aR antibody.
Similarly, we did not detect any changes of C5aR
expression in the permeabilized macrophages retrieved
from different groups of mice (Fig. 5B).
To examine the effect of C5aR siRNA adenovirus on
interstitial macrophages, we isolated leukocytes from
whole-lung digest and evaluated C5aR expression in the
gated interstitial macrophages (Fig. 6). Both nonper-
meabilized and permeabilized conditions were per-
formed for the staining of C5aR. As shown in Fig. 6,
interstitial macrophages represent 10–15% of lung
leukocytes, and C5aR expression in these cells was not
altered by C5aR in vivo silencing. We and others (40,
44–46) have previously reported that alveolar macro-
phages were not targeted by adenovirus because of the
absence of coxsackievirus and adenovirus receptors
(CARs) on the surfaces of macrophages. Thus, it ap-
pears that the decreased C5aR expression observed
with C5aR-siRNA in vivo silencing was primarily due to
the suppressed expression of C5aR on alveolar and
bronchial epithelial cells (Fig. 4).
DISCUSSION
RNA interference (RNAi) is an emerging technology
that selectively inhibits targeted gene expression in vitro
and in vivo. Several viral vectors have been used to
induce RNAi silencing in cultured cells and in experi-
mental animals, including lentivirus (47, 48), retrovirus
(49), adenovirus (50–53), and adenovirus-associated
viruses (54, 55). Under conditions of lung inflamma-
tion (chronic or acute), adenovirus-mediated local
gene delivery appears to be a promising tool for the
study and the treatment of inflammatory disorders
(56–59). In the current study, we used siRNA-express-
ing adenovirus to specifically knock down mRNA and
protein for C5aR, which has been demonstrated to be a
key regulator of IgGIC-induced lung injury (60).
C5aR is present in various cell types, including both
myeloid- and nonmyeloid-derived cells. Up-regulation
of C5aR occurs under several conditions. For example,
during experimental sepsis (cecal ligation and punc-
ture), C5aR is strongly induced in the lung, liver,
kidney, and heart (34). In this study, we report for the
first time that, in a murine model of acute lung injury
induced by intrapulmonary IC deposition, C5aR ex-
Figure 6. Flow cytometric analysis of in vivo C5aR-siRNA silencing on C5aR expression in interstitial macrophages. Whole-lung
leukocytes were isolated as described in Materials and Methods. As shown by F4/80 gating, interstitial macrophages represent
10–15% of whole-lung leukocytes. Lung leukocytes were treated with or without 0.1% saponin to examine C5aR expression
in interstitial macrophages under both nonpermeabilized (A) and permeabilized (B) conditions. No change of C5aR expression
was found among groups under both conditions. Experimental data represent measurements from 4 mice/group.
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pression is up-regulated in the lung and that such
up-regulation can be linked to the requirement of C5a
for the full development of injury. With the adminis-
tration of C5aR-siRNA-expressing virus into mouse
lung, IC-induced C5aR up-regulation in bronchial and
epithelial cells, but not in lung macrophages, was
abolished. Accordingly, the degree of injury [repre-
sented by neutrophil accumulation in the lung (MPO)
and vascular permeability index] was attenuated. The
results are consistent with the previous study (37) from
our laboratory that showed similarly decreased lung
injury after C5aR antagonist treatment. Thus, the inter-
action of C5a/C5aR is crucial for the complement-
mediated lung injury.
Both primary alveolar macrophages and alveolar
epithelial cells have been studied for the effects of C5a
on chemokine production in vitro (7, 8, 22). Macro-
phages do not express receptors for the coxsackie virus
and usually are not targets for adenovirus infection (45,
46). In our studies, we did not observe evidence for
down-regulation of C5aR expression in alveolar macro-
phages and interstitial macrophages isolated from con-
trol virus and C5aR-siRNA-virus-infected mice (Figs. 5
and 6). However, a substantially attenuated C5aR signal
was detected in the bronchial and alveolar epithelial
cells in the lungs of the C5aR-siRNA-silenced mice (Fig.
4C, D). Thus, the decreased cytokines and chemokines
production observed in the C5aR-silenced mice might
be due to the down-regulation of C5aR in lung epithe-
lial cells. It is known that of the CXC chemokines,
MIP-2 and KC are strong chemoattractants for the
recruitment of neutrophils into the inflamed lung (6),
and it is also known that alveolar epithelial cells via
C5aR may contribute significantly to proinflammatory
chemokines and chemokines in the lung after IgGIC
deposition (22). The reduction of KC expression ap-
peared to account for the decreased MPO values ob-
served in the silenced mice. It is also possible that, in
the setting of IgGIC-induced acute lung injury, alveolar
epithelial cells interact with alveolar macrophages to
bring about optimal production of chemokines and
cytokines. In our experiments with C5aR-siRNA silenc-
ing, TNF- expression was decreased, which would be
expected to cause down-regulation of these adhesion
molecules, thereby inhibiting neutrophil migration.
Taken together, our data suggest that in the murine
model of IgGIC-induced acute lung injury, the comple-
ment activation product C5a participates in a regula-
tory network of cytokine, chemokine, and adhesion
molecule expression. By interaction with C5aR, C5a
induces strong expression of proinflammatory media-
tors, which cause neutrophil accumulation and subse-
quent lung injury. By introducing the silencing C5aR-
siRNA into the lung, the interaction of C5a with C5aR
was not only interrupted but the whole network of
inflammatory response was impaired, thereby amelio-
rating the harmful effects of C5a and the downstream
events. The up-regulation of C5aR expression during
the development of lung injury induced by IgG-IC
deposition appears to be an essential event in the chain
of inflammatory reactions. However, as shown in our
recent study (61), the essential role of C5aR for the
development of lung inflammation might only be lim-
ited to complement activation-driven models, as we did
not see a significant role of C5aR in LPS-induced lung
injury. Based on the current data, it appears that
adenovirus-mediated in vivo silencing of C5aR could
serve as a useful tool to study the mechanisms of lung
inflammation and might also be an alternative strategy
for the treatment of disorders related to complement
activation.
Finally, we have shown that the cyclical peptide
inhibitor of C5aR (62) attenuates IgGIC-induced lung
injury in mice (37). However, this inhibitor has not
been commercialized for a variety of reasons. The
pharmacokinetics of the compound have not been
adequately developed in rodents or humans. Further-
more, phase Ib clinical trials involving patients with
rheumatoid arthritis failed to show clinical efficacy
(63). Therefore, it is unlikely that this compound will
be used in humans, even though in a variety of animal
models involving complement-dependent inflamma-
tory diseases in rodents, it was considered efficacious
(64, 65). It is possible that “gene therapy” as described
in this study might ultimately be tested in humans with
pulmonary inflammatory diseases (such as asthma,
chronic obstructive pulmonary disease, acute respira-
tory distress syndrome, and acute lung injury) where
there are indications of a C5a presence.
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